Atrevia® Trio Cats Spot On Small

Multi-Action Topical Ecto-endoparasite with 12 Weeks of Protection

Cats

Topical Solution

Formulation

Fluralaner 112.50 mg, moxidectin 5.60 mg, praziquantel 36.00 mg, excipients q.s.ad 0.40 mL.

Indications

For the treatment and control of mixed infestations caused by endoparasites and ectoparasites in cats, whenever concomitant action is required against ticks (Ixodes ricinus, Ixodes holocyclus, Ixodes hexagonus, Rhipicephalus sanguineus and Dermacentor reticulatus), fleas (Ctenocephalides felis), mites of skin (Demodex gatoi, Demodex cati, Lynxacarus radovskyi and Notoedres cati) and ear (Otodectes cynotis), gastrointestinal nematodes (Toxocara cati, Toxocara malaysiensis, Ancylostoma tubaeforme, Ancylostoma braziliense, Ancylostoma ceylanicum, Uncinaria stenocephala, Toxascaris leonina, Trichuris campanula and Trichuris serrata) and lungworms (Aelurostrongylus abstrusus, Troglostrongylus brevior and Eucoleus aerophilus), heartworm larvae (Dirofilaria immitis) and cestodes (Dipylidium caninum, Taenia taeniaeformis). The action against ectoparasites lasts 12 weeks. When administered repeatedly at 12-week intervals, it continuously prevents heartworm disease caused by Dirofilaria immitis (heartworm)

Dosage and Administration

Topically, at the rate of 1 pipette for cats between 1.2 and 2.8 kg live weight, every 12 weeks.

Commercial Presentation
Box x 1 Pipette, Box x 5 Pipettes.